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Monika Stein1, Wolfgang Holtmeier2, Roland Kaufmann1 and Jens Gille1
Cytoskeletal polymers control a wide range of cellular functions, including proliferation, migration, and gene
expression. As changes in endothelial cell shape and motility are required to form vascular networks, we
hypothesized that disassembly of actin filaments or microtubules may impact endothelial vascular endothelial
growth factor (VEGF) receptor-2 (VEGFR2) expression as a critical determinant of angiogenesis. We therefore
investigated the effect of actin filament- and microtubule-disrupting agents on VEGFR1 and VEGFR2 expression
by endothelial cells. Microtubule (MT) disassembly greatly inhibited endothelial VEGFR2 expression, whereas
VEGFR1 expression levels remained largely unchanged. These suppressive effects were neither conveyed by
increased VEGFR2 shedding nor by shortened protein half-life, suggesting that transcriptional mechanisms
account for the observed effects. In line with this conclusion, MT disruption significantly suppressed
endothelial VEGFR2 mRNA accumulation. The treatment considerably decreased transcriptional activity of
50-deletional VEGFR2 promoter gene constructs. MT disruption-mediated repression was conveyed by a GC-rich
region harboring two consensus Sp1-binding sites. Electrophoretic mobility-shift assay analysis demonstrated
that constitutive Sp1-dependent DNA binding is decreased by MT disassembly. In addition, we provide
evidence for additional post-transcriptional regulatory mechanisms, as the VEGFR2 mRNA half-life is
significantly reduced by MT-disrupting agents. Hence, both inhibition of the rate of gene transcription and
increased mRNA turnover represent critical molecular mechanisms by which MT disruption inhibits VEGFR2
expression.
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INTRODUCTION
Vascular endothelial growth factor (VEGF) and its receptors
are crucial regulators of blood vessel formation during
embryogenesis as well as angiogenic sprouting in inflamma-
tory diseases, cancer, and wound repair (Carmeliet and Jain,
2000; Yancopoulos et al., 2000). The VEGF family members
are secreted glycoproteins, mediating vascular permeability,
endothelial cell proliferation, and migration, and act as a
critical survival factor for endothelial cells.
The biological effects of VEGF are mediated primarily
through interaction with three structurally related receptor
tyrosine kinases, VEGF receptor-1 (VEGFR1), VEGFR2, and
VEGFR3 (Ferrara, 1999; Shibuya et al., 1999). VEGFR1 is a
positive regulator of macrophage migration and was de-
scribed as a regulator of VEGFR2 signaling as for example by
functioning as a decoy receptor (Rahimi et al., 2000).
VEGFR2 is thought to mediate the major growth effects and
permeability of VEGF, whereas VEGFR3 is fundamental for
lymphatic vessel formation (Millauer et al., 1993; Walten-
berger et al., 1994). While VEGFR2 is only detectable at
relatively low levels in the adult vasculature (Detmar, 1996),
it may be markedly upregulated by blood vessels during
chronic inflammation, tumor growth, and wound repair
(Ferrara, 1999; Shibuya et al., 1999). VEGF is secreted by
various different cell types; however, VEGFR2 expression is
largely restricted to vascular endothelial cells. Endothelial
expression of VEGFR2 closely parallels VEGF expression in
angiogenic responses (Petrova et al., 1999). As a result,
suppression of the VEGF/VEGFR2-signaling pathway is
intensely explored as therapeutic prospect to interfere
with new blood vessel formation (Schlaeppi and Wood,
1999).
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Microtubules (MTs), composed of a-tubulin and b-tubulin,
are cytoskeletal elements that control a wide range of
fundamental cellular functions, including intracellular trans-
port, proliferation, migration, cell division, cell signaling as
well as gene expression. MTs are important targets for cancer
chemotherapeutic drugs, such as vinca alkaloids and taxanes.
These MT-targeted drugs are extensively used as cytotoxic
agents for treatment of various human malignancies, for
example, breast and lung carcinoma, melanoma, or head and
neck cancer. Most of these compounds effectively suppress
MT dynamics, causing an impairment of the metaphase-
to-anaphase transition that eventually leads to tumor cell
apoptosis (Jordan and Wilson, 2004). In addition, modulating
MT dynamics may critically suppress interphase MT
functions, such as the transport of p53 protein (Giannakakou
et al., 2002).
It has been demonstrated consistently that MT-targeted
drugs, such as taxanes or vinca alkaloids, can exert profound
antiangiogenic activities (Bayless and Davis, 2004; Davis
et al., 2005). However, the underlying mechanisms of these
effects are yet to be elucidated in detail. The work of Bayless
and Davis (2004) assumes an increased activation of the
small GTPase RhoA, leading to apoptosis of endothelial cells
in response to MT-disrupting agents (Davis et al., 2005).
However, Pasquier et al. (2004) argued that the antiangio-
genic activity of paclitaxel, an MT-stabilizing drug, might be
associated with its cytostatic effect initiating a mitochondrial
apoptotic signaling pathway. In contrast, additional experi-
mental evidence suggests that the contribution of apoptosis to
the antiangiongenic effect of MT-disrupting agents lies within
a range of 15% at most (Bourgarel-Rey et al., 2001; Flusberg
et al., 2001), suggesting that the antiapoptotic effects alone
may hardly explain the whole antiangiogenic action.
As endothelial VEGFR2 expression is increasingly recog-
nized as a key component of the VEGF/VEGFR-signaling
system during tumor angiogenesis (Detmar et al., 1994; Fava
et al., 1994), we hypothesized that MT-targeted drugs may
just as well control angiogenesis, at least in part, by targeting
VEGFR2 expression.
To test this hypothesis, human vein endothelial cells
(HUVECs) were treated with different MT-targeted drugs. We
found that the MT-disrupting agents nocodazole and vinblas-
tine downregulated VEGFR2 mRNA expression, whereas
actin-targeted drugs, such as latrunculin A, failed to do so.
Inhibitory effects on the transcriptional activity of the
VEGFR2 promoter are shown to be conferred by an element
located between bp 60 and 30, containing two consensus
Sp1 transcription factor-binding sites. As constitutive Sp1-
dependent DNA binding to this sequence is decreased by
MT-disrupting drugs, VEGFR2 gene expression may be
inhibited by repressing Sp1-dependent DNA binding and
transactivation. Furthermore, these agents increased down-
regulation of the tyrosine kinase receptor VEGFR2 by
inducing VEGFR2 mRNA instability.
Altogether, our results confirm that MT-destabilizing drugs
mediate their antiangiogenic effects in part via reduced
VEGFR2 expression in human endothelial cells interfering
with transcriptional activity as well as the mRNA stability of
the tyrosine receptor, highlighting the important role of MT
function in the regulation of angiogenesis and therefore in the
treatment of cancer.
RESULTS
MT-disrupting, but not actin-targeted, agents inhibit VEGFR2
expression by human endothelial cells
To explore whether the antiangiogenic properties of the MT-
disrupting (nocodazole, vinblastine, and colchicine) and
actin-disrupting agents (latrunculin A and cytochalasin D)
are mediated in part through inhibition of endothelial
VEGFR2 expression, we studied the effects of these drugs
on the protein expression of VEGFR2 and VEGFR1 by
HUVECs by western blot analyses. The concentrations of
the respective ligands used are comparable to those used in
previous studies (Baguley et al., 1991; Manie et al., 1993;
Rao et al., 1997; Subbaramaiah et al., 2000; Samarakoon and
Higgins, 2002). We here provide strong evidence for a
significant downregulation of basilar VEGFR2 protein ex-
pression by MT-disrupting agents (vinblastine, nocodazole,
and colchicine) in a time- and concentration-dependent
manner, whereas VEGFR1 protein expression was not
discernibly affected. In contrast, actin-targeted agents latrun-
culin A and cytochalasin D failed to exert inhibitory effects
(Figure 1). These findings are further supported by fluores-
cence-activated cell sorting analyses, revealing an effective
inhibition of basal VEGFR2 surface expression by treatment
with MT-disrupting agents (Figure 2). For other surface
receptors, such as the IL-6 receptor or the tumor necrosis
factor-a receptor, receptor shedding has been shown to
constitute an important way of receptor downregulation
(Franchimont et al., 2005; Peiretti et al., 2005). To explore
whether such a mechanism mediated VEGFR2 downregula-
tion in response to MT disassembly, we measured the portion
of soluble VEGFR2 in the supernatants of HUVECs after
treatment with MT-disrupting agents for 24 hours. Interest-
ingly, however, the proportion of soluble VEGFR2 was rather
reduced after treatment, which might be explained by the
lack of constant supply due to a reduced translation of the
receptor (Figure 3). A decrease in protein half-life as an
underlying mechanism of reduced VEGFR2 expression in
response to MT-disrupting agents was also ruled out in
respective protein half-life analyses (Figure 4). We rather
could demonstrate a slight increase in VEGFR2 protein half-
life, therefore ruling out changes in protein half-life as a
mechanism of reduced VEGFR2 expression. Our data there-
fore suggest that transcriptional mechanisms accounted for
VEGFR2 suppression in response to MT-disrupting agents.
MT-disrupting agents suppress steady-state VEGFR2 mRNA
levels in human endothelial cells
To explore whether inhibition of VEGFR2 protein synthesis
by MT-disrupting agents corresponded to comparable
changes of specific mRNA expression, we analyzed the
effects of MT-disrupting agents on steady-state VEGFR2
transcript levels in HUVECs (Figure 5a). In line with our
protein expression data, the MT-disrupting agent nocodazole
suppressed VEGFR2, but not VEGFR1, mRNA expression.
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To determine whether post-transcriptional mechanisms can
account for inhibitory properties of MT-disrupting agents on
VEGFR2 expression, we analyzed their effects on VEGFR2
mRNA turnover. After inhibition of gene transcription by
addition of actinomycin D, the quantity of VEGFR2 mRNA
expression at subsequent time points was examined
and mRNA half-lives were determined by calculating
linear regressions to a log-linear plot of mRNA expression
as a function of time (Figure 5b). Significantly, there was a
reduction of VEGFR2 mRNA half-life after treatment with the
MT-disrupting agents. Therefore, the increase in VEGFR2
mRNA turnover as a result of MT-disrupting agents may lead
to repression of VEGFR2 mRNA accumulation and subse-
quent protein expression. While reduced mRNA half-life
can mediate, at least in part, the inhibitory properties of MT-
disrupting agents on mRNA steady-state expression, inhibi-
tion may additionally be mediated at the transcriptional level.
Inhibition of VEGFR2 promoter activity in response to
MT-disrupting agents is conveyed by an Sp1-binding site
To examine the molecular mechanisms regulating VEGFR2
gene transcription after exposure to MT-disrupting agents, a
range of 50-deletional VEGFR2 promoter-based reporter
gene constructs was transiently transfected into HUVECs
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Figure 1. Effects of MT-disrupting agents on the VEGFR2 protein expression in HUVECs. Representative western blot analyses of endothelial cells that were
left untreated (solvent only) or were treated with both (a) nocodazole and (b) vinblastine in concentration- and time-dependent manner as indicated; in
addition, the effects of latrunculin A (c) are shown with increasing concentrations (24 hours) as indicated, and those of cytochalasin D (2 mM) (d) at different
time points. Total cellular protein was separated on 8% SDS–PAGE gel. VEGFR1, VEGFR2, and tubulin protein were detected by enhanced chemiluminescence.
Comparable results were obtained from three independent experiments.
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Figure 2. Effects of MT-disrupting agents on VEGFR2 surface expression by
HUVECs. Flow-cytometric analyses of VEGFR2 expression; HUVECs were left
untreated (solvent only, black line, to the right) or were treated with different
concentrations of (a) nocodazole (0.01mM, green line; 0.1mM, blue line; and
1mM, yellow line) and (b) vinblastine (0.01 mM, green line; 0.1 mM, blue line;
1mM yellow line; and 10 mM, pink line). Antibody isotype control stainings are
displayed as red lines to the left; histograms represent absolute cell counts
(vertical axis, linear scale) versus fluorescence intensity (horizontal axis, log10
scale). One representative experiment out of three is shown.
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Figure 3. Effect of nocodazole on the soluble VEGFR2 expression in
supernatants of HUVECs. Soluble VEGFR2 protein content was assayed in
culture supernatants by sVEGFR2 ELISA (R&D Systems) according to the
manufacturer’s instructions. HUVECs were left untreated (solvent only,
DMSO 0.1%) or were treated with nocodazole (at 2mM). Mean values from
triplicate experiments are depicted±SEM.
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(Figure 6a). Studies of the respective luciferase (Luc)
expressions in untreated controls showed significant baseline
activity of the 1.1 kb/þ286-bp VEGFR2 Luc construct that
was reduced in response to vinblastine to about 60% (Figure
6a). Shorter constructs, including the 60/þ 268-bp VEGFR2
construct, showed less constitutive expression compared with
the longer reporter plasmids; however, considerable basal
activity was retained, including the ability to significantly
suppress reporter gene activity. These results indicate that
critical gene-regulatory elements necessary for both consti-
tutive expression and vinblastine-mediated inhibition are
located 30 of the 60 bp. As two adjacent Sp1 consensus
binding sites are located at positions 58 and 44 bp (Figure
6a), we next explored the potential impact on transcriptional
activation of a mutant 60/þ 268bp Luc construct, in which
critical two nucleotide mutations were incorporated within
the Sp1 sites. Analyses of the mutant 60/þ 268-bp construct
showed loss of both basal and vinblastine-mediated inhibi-
tion of reporter gene expression. These data clearly suggest
that MT-disrupting, agent-conveyed inhibition of VEGFR2
transcription is Sp1 site-dependent.
Constitutive Sp-dependent binding activity to the 85/31-bp
VEGFR2 promoter sequence is reduced in the presence of
MT-destabilizing agents
We next explored whether Sp-dependent binding to the 85/
31-bp VEGFR2 promoter sequence is modulated by
treatment with MT-disrupting agents. A double-stranded
DNA probe corresponding to the Sp1 cluster was used in
electrophoretic mobility-shift assays to investigate the effects
of the MT-disrupting agents nocodazole, vinblastine, and
colchicine on Sp-dependent binding (Figure 6b). During
incubation with nuclear extracts of untreated HUVECs,
constitutive DNA-binding activity of distinct complexes was
observed (lane 1). In lysates of cells treated with the MT-
disrupting agents for 1 hour, a significant decrease in DNA-
binding activity was detected (lanes 2–4). To determine
whether decreased Sp-binding activity to the GC-rich core
promoter in response to MT-disrupting agents was mediated
by changes in nuclear levels of Sp1 transcription factor, we
analyzed nuclear HUVEC proteins for Sp1 expression in
response to nocodazole or vinblastine (Figure 6c). Both MT-
disrupting agents did not induce notable changes in Sp1
protein expression. Together, these findings provide strong
evidence that inhibition of VEGFR2 gene transcription in
response to MT-disrupting agents is conferred by two distinct
mechanisms. MT-targeted drugs inhibit VEGFR2 expression
by both repressing Sp1-dependent transactivation and by
increasing mRNA turnover.
DISCUSSION
Mitotic-spindle MTs belong to the most successful targets for
anticancer therapy. Antimitotic agents that bind to tubulin
and disrupt MT dynamics are important components for the
treatment of different human tumor entities. The two main
groups of anti-MT agents used in the treatment of cancer are
on the one hand the MT stabilizers, such as the taxanes, and
on the other hand MT destabilizers, such as vinca alkaloids.
All of these compounds block mitosis at the metaphase/
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Figure 4. Effect of nocodazole on protein half-life in HUVECs. Human
umbilical vein endothelial cells were incubated in the presence or absence of
nocodazole (10 mM) for 3 hours and incubated for 0, 0.5, 1, 1.5, and 2.0 hours
with fresh media containing cycloheximide (10 mgml1). Total cellular
protein was separated on 8% SDS–PAGE gel. VEGFR2 and tubulin protein
were detected by enhanced chemiluminescence. VEGFR2 protein remaining
at these time points was determined by densitometric scanning, the results of
which were normalized to amounts of tubulin. Comparable results were
obtained from three independent experiments.
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Figure 5. Vascular endothelial growth factor receptor-2, but not VEGFR1,
mRNA expression is inhibited by MT-disrupting agents. (a) Reverse
transcriptase–PCR analyses were performed on total RNA extracted from
sub-confluent cell cultures. HUVECs were left untreated (solvent only) or
were treated with nocodazole in a time- and concentration dependent
manner as indicated. Results were confirmed in three independent sets of
experiments. (b) HUVECs were incubated in the presence or absence of
nocodazole (10mM) for 3 hours and incubated for 0, 1, 2, 3, 4, and 5hours
with fresh media containing actinomycin D (10 mgml1). Then RT–PCR
analyses for VEGFR2/GAPDH of total RNA extracted from sub-confluent cell
cultures were performed. The PCR products were size-fractionated on 2%
agarose gels and visualized under a UV transilluminator. VEGFR2 mRNA
remaining at these time points was determined by densitometric scanning,
and was normalized to the respective levels of GAPDH mRNA expression.
The half-life of VEGF/vascular permeability factor mRNA was determined by
calculating linear regressions to a log-linear plot of mRNA expression versus
time. Comparable results were obtained from three independent experiments.
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anaphase transition, finally leading to apoptosis of the tumor
cells by suppression of MT dynamics (Jordan and Wilson,
2004).
Recently, it could be shown that MT-targeted drugs do not
only have a pronounced effect against the tumor cell itself,
but also mediate their therapeutic effects via antiangiogenic
actions, partly at already much lower concentrations than the
maximum tolerated dose of the respective chemotherapeutic.
Wang et al. convincingly showed that the taxane paclitaxel
inhibits angiogenesis at concentrations that do not affect
cellular MT assembly. Wang provided evidence that no
metaphase/anaphase cycle arrest takes place, arguing that a
novel yet unidentified mechanism was responsible for the
antiangiogenic effect (Wang et al., 2003). Recently, Pourroy
et al. could demonstrate that preferably the vinca alkaloid
vinflunine increased the interphase MT dynamics. However,
the molecular determinants connecting MT dynamics and
interphase endothelial cell function are yet to be determined
(Pourroy et al., 2006).
There are only few studies that disclose the molecular
basis for the antiangiogenic action of MT-disrupting agents. In
this context, Bayless and co-workers could show that MT
depolymerization by colchicine, vinblastine, or nocodazole
leads to rapid collapse of capillary tube networks in vitro as
well as in vivo. In addition, the studies revealed that
activation of the small GTPase RhoA by these drugs
eventually resulted in endothelial cell apoptosis (Bayless
and Davis, 2004). In this context, it must be taken into
account that RhoA is a downstream target of the VEGFR2.
Davis et al. (2005) were able to demonstrate that disruption of
MTs by nocodazole inhibited the tumor necrosis factor
a-stimulated vascular cell adhesion molecule-1 and intracel-
lular adhesion molecule-1 expression necessary for endothe-
lial chemokinesis and chemotaxis.
There is a growing body of evidence that the cytoskeleton
is critically involved in the propagation of signals altering
gene expression. Specifically, it has been recently shown that
the transcription of different genes, such as c-myc, cyclo-
oxygenase-2, and plasminogen activator inhibitor type 1, are
tightly regulated by cytoskeletal dynamics (Manie et al.,
1993; Rao et al., 1997; Subbaramaiah et al., 2000;
Bourgarel-Rey et al., 2001; Samarakoon and Higgins,
2002). Up to now, however, only limited data are
available which provide a more detailed understanding
about the molecular basis of cytoskeleton-controlled gene
expression. In this regard, Subbaramaiah et al. (2000) were
among the first to demonstrate that MT-disrupting agents can
induce binding of the transcription factor activator protein-1
to the cAMP-response element of the cyclooxygenase-2-
promoter, providing first evidence for a MT-dependent
regulation of transcription factor binding. In a comparable
manner, MT depolymerization by vinblastine or
nocodazole was demonstrated to mediate activation and
nuclear translocation of NF-kB, subsequently resulting in
c-myc expression by epithelial mammary cells (Bourgarel-
Rey et al., 2001).
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Figure 6. MT-destabilizing agents inhibit VEGFR2 promoter activity via reduction of constitutive Sp-dependent binding to the –85/–31 bp sequence.
(a) Analyses of 50-deletional and mutational VEGFR2 promoter-based luciferase (Luc) constructs in HUVECs. Schematic representation of the respective reporter
gene constructs on the left, coordinates with respect to the transcription start site in the center, and the relative Luc activities (expressed as % basal activity of the
1.1/þ 268 construct) in graphic format on the right: black bars, untreated controls; white bars, vinblastine-treated cells (mean±SD of three independent
duplicate assays); Student’s t-test, *Po0.005; NS, not significant. (b) Representative electrophoretic mobility-shift assays using nuclear extracts of untreated,
vinblastine-treated (at 2mM, 1 hour), nocodazole-treated (at 10 mM, 1 hour), and colchicine-treated (at 2 mM, 1 hour) HUVECs; competition with unlabeled 63/
31-bp wild-type DNA (lane 5; at 100 molar excess), or with unlabeled excess double-stranded Sp1 consensus oligonucleotides (lane 6; at a final concentration
of 0.35 mmol l1). A representative autoradiography from three independent experiments is shown. Formation of Sp-dependent binding complexes is indicated
by arrows to the left. (c) Representative western blot analyses of endothelial cells that were left untreated (solvent only) or were treated with nocodazole (10 mM,
1 hour) or vinblastine (2 mM, 1 hour). Nuclear protein was separated by 8% SDS–PAGE. Sp1 protein was detected by enhanced chemiluminescence. Comparable
results were obtained from three independent experiments.
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Our data identify VEGFR2 expression as a novel target of
MT-disrupting agents. As VEGFR2 constitutes a major
receptor involved in endothelial cell survival, proliferation,
and vascular permeability, VEGFR2 suppression by MT-
disrupting agents may represent a critical mechanism by
which their established antiangiogenic effects are mediated
in vivo.
We provide strong evidence that the VEGFR2 suppression
is mediated by two distinct mechanisms influencing VEGFR2
mRNA accumulation in HUVECs after treatment with MT-
disrupting drugs. First, we demonstrate that mRNA half-life of
the tyrosine kinase receptor is significantly reduced after drug
treatment, whereas post-translational mechanisms seemed to
be not involved. Thus, a decrease in the intracellular stability
of mRNA may participate in the regulation of VEGFR2 mRNA
expression via modulating MT dynamics. These data are in
line with the work of Ozawa et al. (1997) who showed that
downregulation of endothelin-B receptor by MT-disrupting
agents was regulated in part by reducing mRNA half-life.
These findings were bolstered by the work of Bandyopadhyay
et al. (2003) demonstrating that taxol may suppress bcl-2
mRNA expression through inactivation of bcl-2 mRNA-
stabilizing factors. Up to now, however, it was not possible
to identify trans-acting proteins involved in bcl-2 mRNA
stabilization. Pertinent to these findings, Shannon et al.
(1998) revealed that disruption of the cytoskeleton by
nocodazole or colchicine led to marked decrease in
surfactant protein mRNA stability in alveolar type II cells.
Thus, the available evidence supports our assumption that
MT-targeted drugs might indeed affect VEGFR2 mRNA
stability, thereby closely linking the cytoskeleton to VEGFR2
expression. Due to the pivotal role of VEGFR2 in endothelial
cell function and tumor angiogenesis, VEGFR2 mRNA
stability may constitute an additional target of future
antiangiogenic strategies. Second, our data indicate that
MT-disrupting agents inhibit VEGFR2 transcription, which is
conferred by an element located between 60 and 30 bp.
As this sequence contains consensus Sp1-binding sites, MT-
disrupting agents may likely block VEGFR2 gene expression
also by repressing Sp1-dependent DNA binding and trans-
activation. The latter interpretation is supported by our
DNA-binding assays, showing decreased Sp1-dependent
activity in response to MT-disrupting agents (Figure 6b). Thus
far, only two reports have been published which connect Sp1
transcription factor to MT dynamics. Contrary to our data,
D’Addario et al. (2003) showed in fibroblast cultures that
disruption of MTs increases filamin A expression and
Sp1-mediated promoter activity, whereas MT-stabilizing
drugs, such as taxanes, inhibit filamin A protein and mRNA
expression. However, in line with our findings, Lacroix et al.
(2002) demonstrated decreased Sp1 DNA-binding activity in
proliferating T cells as a result of nocodazole treatment.
Conceivably, MT-targeted drugs act in a cell-specific manner,
which may explain the divergent results of Lacroix and
D’Addario. Recently, we demonstrated that biomechanical
stimulation leads to endothelial cell survival by upregulating
VEGFR2 expression. Shear stress-induced VEGFR2 transcrip-
tion was mediated by augmented Sp1 VEGFR2 promoter-
binding activity. Generally, biomechanical stimulation is
associated with cytoskeleton rearrangement, therefore MT
disruption might physically explain the decrease of Sp1
binding capacity to the VEGFR2 promoter (Urbich et al.,
2003).
In conclusion, our data identify VEGFR2 expression as an
additional target of MT-disrupting agents in endothelial cells.
This clarification may provide an additional and important
explanation for the antiangiogenic action conveyed by MT-
disrupting agents, and will likely help to better define the
therapeutic potential and clinical indications of MT-targeted
agents in vascular-dependent diseases. Our ongoing experi-
ments are aimed to identify the link between Sp1 function
and the cytoskeleton as well as elucidation of the possible
mechanisms by which MT-targeted drugs inhibit Sp1 DNA
binding.
MATERIALS AND METHODS
Cell culture
Human umbilical vein endothelial cells were purchased from
PromoCell (Heidelberg, Germany), and cultured until fifth passage
at 37 1C and 5% CO2 in endothelial cell growth medium (Cambrex).
Institutional approval was not required for experiments.
Fluorescence-activated cell sorting analysis
Human umbilical vein endothelial cells were incubated with mouse
anti-human VEGFR2 mAb (FAB857P, 1:200 dilution; R&D Systems,
Inc., Minneapolis, MN) or isotype control mouse anti-human IgG1
(Caltag Laboratories, Karlsruhe, Germany) for 30minutes on ice.
Cells were then incubated with FITC-conjugated affinity-purified
goat F(ab0)2 anti-mouse IgG (Dako, Hamburg, Germany) at a 1:100
dilution for 30minutes, and were subsequently analyzed by a BD
FACScan Cytometer (Becton Dickinson, Franklin Lakes, NJ). Non-
viable cells were identified and excluded by propidium iodide
staining.
Western blot analysis
Protein extracts were prepared as described previously. The
membranes were incubated with the indicated primary antibodies
(Sp1, clone PEP2; Santa Cruz, Heidelberg, Germany; VEGFR1
and VEGFR2; R&D Systems; and tubulin antibody; LabVision
Corp., Fremont, CA), followed by incubation with horseradish
peroxidase-conjugated secondary antibodies (anti-mouse or anti-
rabbit IgG; Amersham Biosciences, Piscataway, NJ, anti-goat; Dako).
The blots were developed using the enhanced chemiluminescence
detection system according to the manufacturer’s instructions
(Amersham).
RNA extraction and RT–PCR
For reverse transcriptase–PCR (RT–PCR) analyses, 150 ng of total
RNA were obtained from HUVECs using the RNeasy Mini kit
(Qiagen, Hilden, Germany), and reverse transcribed with a
recombinant homodimeric viral reverse transcriptase from the
cMaster RT–PCR kit (Eppendorf, Hamburg, Germany). Specific
primers were used for amplification of a 252-bp fragment of human
VEGFR1 cDNA (50-GAACACAGCTCAAGCAAACC-30, 50-GAT
CAAAGTGTCAAGTGGA-30; nucleotides 531–783, accession
number AF063657.2), a 331-bp fragment of human VEGFR2 cDNA
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(50-TTTGGTTCTGTCTTCCAAAGT-30, 50-ATGCTCAGCAGGATGG
CAA-30; nucleotides 3803–4134, accession number M002253.1),
and an 803-bp coding sequence of human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) cDNA (50-GCACCGT
CAAGGCTGAGAAC-30, 50-CCACCACCCTGTTGCTGTAG-30; nu-
cleotides 173–976, accession number BC023632.2). After a hot start
at 94 1C, primers were annealed for 45 seconds (VEGFR1 at 52 1C,
VEGFR2 at 52 1C, and GAPDH at 45 1C) and extended for 45 seconds
at 72 1C. PCR cycle numbers were adjusted for the respective
VEGFR1, VEGFR2, and GAPDH products to assure amplification in
the linear range (23 cycles for VEGFR1 and VEGFR2; 25 cycles for
GAPDH. PCR reactions were carried out with a T3 Thermocycler
(Biometra, Goettingen, Germany). The resultant PCR products were
size-fractionated on 2% agarose gels for VEGFR1 and VEGFR2 and
on 1% gels for GAPDH products, and were subsequently visualized
by a UV transilluminator. Densitometry of bands was quantified
using the public domain Java image-processing program ImageJ
(v1.29s); optical densities of VEGFR2 and VEGFR1 bands were
corrected for loading differences on the basis of the corresponding
GAPDH bands.
Transient transfection and analysis of reporter gene expression
Human umbilical vein endothelial cells (0.8 105well-, 12-well
plates) were transfected with 0.5 mg of appropriate firefly luciferase
construct and 0.15 mg of phRG-TK vector (Promega, Mannheim,
Germany) using SuperFect transfection reagent (Qiagen). Human
VEGFR2 reporter gene constructs were generously provided by Dr C
Patterson (University of North Carolina, Chapel Hill, NC). Twenty-
four hours after transfection, control transfectants were left untreated
and test transfectants were exposed to MT-targeted drugs for
24 hours. The activities of luciferases were measured utilizing the
Dual-Luciferase Reporter Assay System from Promega.
Preparation of nuclear extracts and gel mobility-shift analysis
Human umbilical vein endothelial cells were left untreated or were
incubated with MT-targeted drugs for 60minutes. Nuclear proteins
were extracted as described previously. The DNA-binding reactions
were performed with or without excess of unlabeled competitor, Sp1
consensus oligonucleotide (Promega), and a wild-type oligonucleo-
tide as described previously (Meissner et al., 2004).
Statistical analysis
Data are expressed as mean±SD/SE from X3 independent experi-
ments. Statistical analysis was performed by Student’s t-test.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We are thankful to Dr Cam Patterson (University of North Carolina, Chapel
Hill, NC, USA) for providing VEGFR2 promoter-based Luc reporter gene
constructs. This work was supported by Deutsche Forschungsgemeinschaft
grant Gi 229/6-1 (JG), and grants by the Eberhard and Hilde Ru¨diger Stiftung
(MM) and the Berliner Stiftung fu¨r Dermatologie (MM).
REFERENCES
Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ (1991) Inhibition
of growth of colon 38 adenocarcinoma by vinblastine and colchicine:
evidence for a vascular mechanism. Eur J Cancer 27:482–7
Bandyopadhyay S, Sengupta TK, Fernandes DJ, Spicer EK (2003) Taxol- and
okadaic acid-induced destabilization of bcl-2 mRNA is associated with
decreased binding of proteins to a bcl-2 instability element. Biochem
Pharmacol 66:1151–62
Bayless KJ, Davis GE (2004) Microtubule depolymerization rapidly collapses
capillary tube networks in vitro and angiogenic vessels in vivo through
the small GTPase Rho. J Biol Chem 279:11686–95
Bourgarel-Rey V, Vallee S, Rimet O, Champion S, Braguer D, Desobry A et al.
(2001) Involvement of nuclear factor kappaB in c-Myc induction by
tubulin polymerization inhibitors. Mol Pharmacol 59:1165–70
Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature
407:249–57
D’Addario M, Arora PD, Ellen RP, McCulloch CA (2003) Regulation of
tension-induced mechanotranscriptional signals by the microtubule
network in fibroblasts. J Biol Chem 278:53090–7
Davis HW, VandenBerg E, Reid MD, Roy-Chaudhury P, Edwards JD (2005)
Paclitaxel impairs endothelial cell adhesion but not cytokine-induced
cellular adhesion molecule expression. Ann Vasc Surg 19:398–406
Detmar M (1996) Molecular regulation of angiogenesis in the skin. J Invest
Dermatol 106:207–8
Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW et al.
(1994) Overexpression of vascular permeability factor/vascular endothe-
lial growth factor and its receptors in psoriasis. J Exp Med 180:1141–6
Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B et al. (1994)
Vascular permeability factor/endothelial growth factor (VPF/VEGF):
accumulation and expression in human synovial fluids and rheumatoid
synovial tissue. J Exp Med 180:341–6
Ferrara N (1999) Vascular endothelial growth factor: molecular and biological
aspects. Curr Top Microbiol Immunol 237:1–30
Flusberg DA, Numaguchi Y, Ingber DE (2001) Cooperative control of Akt
phosphorylation, bcl-2 expression, and apoptosis by cytoskeletal
microfilaments and microtubules in capillary endothelial cells. Mol Biol
Cell 12:3087–94
Franchimont N, Lambert C, Huynen P, Ribbens C, Relic B, Chariot A et al.
(2005) Interleukin-6 receptor shedding is enhanced by interleukin-1beta
and tumor necrosis factor alpha and is partially mediated by tumor
necrosis factor alpha-converting enzyme in osteoblast-like cells. Arthritis
Rheum 52:84–93
Giannakakou P, Nakano M, Nicolaou KC, O’Brate A, Yu J, Blagosklonny MV
et al. (2002) Enhanced microtubule-dependent trafficking and p53
nuclear accumulation by suppression of microtubule dynamics. Proc
Natl Acad Sci USA 99:10855–60
Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat
Rev Cancer 4:253–65
Lacroix I, Lipcey C, Imbert J, Kahn-Perles B (2002) Sp1 transcriptional activity
is upregulated by phosphatase 2A in dividing T lymphocytes. J Biol
Chem 277:9598–605
Manie S, Schmid-Alliana A, Kubar J, Ferrua B, Rossi B (1993) Disruption of
microtubule network in human monocytes induces expression of
interleukin-1 but not that of interleukin-6 nor tumor necrosis factor-
alpha. Involvement of protein kinase A stimulation. J Biol Chem
268:13675–81
Meissner M, Stein M, Urbich C, Reisinger K, Suske G, Staels B et al. (2004)
PPARalpha activators inhibit vascular endothelial growth factor receptor-
2 expression by repressing Sp1-dependent DNA binding and transactiva-
tion. Circ Res 94:324–32
Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W
et al. (1993) High affinity VEGF binding and developmental expression
suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis.
Cell 72:835–46
Ozawa F, Kasuya Y, Hama H, Asada S, Inada T, Goto K (1997) Microtubule
dynamics regulates the level of endothelin-B receptor in rat cultured
astrocytes. J Neurochem 69:562–9
Pasquier E, Carre M, Pourroy B, Camoin L, Rebai O, Briand C et al. (2004)
Antiangiogenic activity of paclitaxel is associated with its cytostatic
effect, mediated by the initiation but not completion of a mitochondrial
apoptotic signaling pathway. Mol Cancer Ther 3:1301–10
2090 Journal of Investigative Dermatology (2008), Volume 128
M Meissner et al.
Microtubule-Targeted Drugs Inhibit Angiogenesis via VEGFR2
Peiretti F, Canault M, Bernot D, Bonardo B, Deprez-Beauclair P,
Juhan-Vague I et al. (2005) Proteasome inhibition activates the transport
and the ectodomain shedding of TNF-alpha receptors in human
endothelial cells. J Cell Sci 118(Part 5):1061–70
Petrova TV, Makinen T, Alitalo K (1999) Signaling via vascular endothelial
growth factor receptors. Exp Cell Res 253:117–30
Pourroy B, Honore S, Pasquier E, Bourgarel-Rey V, Kruczynski A, Briand C
et al. (2006) Antiangiogenic concentrations of vinflunine increase the
interphase microtubule dynamics and decrease the motility of endothe-
lial cells. Cancer Res 66:3256–63
Rahimi N, Dayanir V, Lashkari K (2000) Receptor chimeras indicate that the
VEGFR-1 modulates mitogenic activity of VEGFR-2 in endothelial cells.
J Biol Chem 275:16986–92
Rao P, Falk LA, Dougherty SF, Sawada T, Pluznik DH (1997) Colchicine
downregulates lipopolysaccharide-induced granulocyte-macrophage colony-
stimulating factor production in murine macrophages. J Immunol 159:3531–9
Samarakoon R, Higgins PJ (2002) MEK/ERK pathway mediates cell-shape-
dependent plasminogen activator inhibitor type 1 gene expression upon
drug-induced disruption of the microfilament and microtubule networks.
J Cell Sci 115(Part 15):3093–103
Schlaeppi JM, Wood JM (1999) Targeting vascular endothelial growth factor
(VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal
antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer
Metastasis Rev 18:473–81
Shannon JM, Pan T, Edeen KE, Nielsen LD (1998) Influence of the
cytoskeleton on surfactant protein gene expression in cultured rat
alveolar type II cells. Am J Physiol 274(1 Part 1):L87–96
Shibuya M, Ito N, Claesson-Welsh L (1999) Structure and function of vascular
endothelial growth factor receptor-1 and -2. Curr Top Microbiol
Immunol 237:59–83
Subbaramaiah K, Hart JC, Norton L, Dannenberg AJ (2000) Microtubule-
interfering agents stimulate the transcription of cyclooxygenase-2.
Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein
kinase pathways. J Biol Chem 275:14838–45
Urbich C, Stein M, Reisinger K, Kaufmann R, Dimmeler S, Gille J (2003) Fluid
shear stress-induced transcriptional activation of the vascular endothelial
growth factor receptor-2 gene requires Sp1-dependent DNA binding.
FEBS Lett 535:87–93
Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH
(1994) Different signal transduction properties of KDR and Flt1, two
receptors for vascular endothelial growth factor. J Biol Chem 269:
26988–95
Wang J, Lou P, Lesniewski R, Henkin J (2003) Paclitaxel at ultra
low concentrations inhibits angiogenesis without affecting cellular
microtubule assembly. Anticancer Drugs 14:13–9
Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000)
Vascular-specific growth factors and blood vessel formation. Nature
407:242–8
www.jidonline.org 2091
M Meissner et al.
Microtubule-Targeted Drugs Inhibit Angiogenesis via VEGFR2
